Integrated Report

Full Report

For viewing (PDF/9187KB)

For printing (PDF/9284KB)

By Section

• Profile
• From Sumitomo Dainippon Pharma to Sumitomo Pharma（PDF/1,664KB)
• History of Value Creation and Growth（PDF/551KB)
• Corporate Mission / Corporate Culture（PDF/430KB)
• Main Products（PDF/549KB)
• Financial Highlights（PDF/480KB)
• Non-Financial Highlights（PDF/464KB)
• Table of Contents / Editorial Policy（PDF/541KB)

• Value Creation Strategies
• Changes in the Environment Surrounding Pharmaceutical Companies（PDF/561KB)
• Opportunities and Risks（PDF/420KB)
• Business Model（PDF/713KB)
• Message from the President（PDF/1,017KB)
• Financial Policy (Message from the President)（PDF/546KB)
• Information Disclosure Based on the TCFD Recommendations (Responses to Climate Change)（PDF/429KB)
• Feature: Fostering "CHANTO," the capability to deliver the highest performance（PDF/664KB)
• Sustainability and Materiality（PDF/490KB)
• Mid-term Business Plan（PDF/425KB)

• Practice & Performance
• Mid-term Business Plan 2022（PDF/418KB)
• Basic Policy I
  Establishment of growth engine（PDF/5,284KB)
• Strategy 1 Enhance innovation base with new approaches to drug discovery
• Strategy 2 Deliver the highest performance of clinical development
• Message from the Executive Officers
• Strategy 3 Pipeline expansion through strategic investment
• Strategy 4 Regional strategy centering in Japan, North America and China
• Strategy 5 Launch frontier business
• Basic Policy II
  Building of flexible and efficient organization（PDF/2,873KB)
• Flexible and efficient organization and operations
• Corporate culture and talent to drive innovation
• Message from the Executive Officer in Charge of Human Resources
• Digital transformation
• Environment（PDF/708KB)
• Contribution to Societies（PDF/871KB)

• Governance
• Corporate Governance（PDF/2,067KB)

• Financial & Corporate Information
• Ten-Year Summary of Selected Financial Data（PDF/431KB)
• Operating Results and Financial Condition, and Business Risks（PDF/457KB)
• Consolidated Financial Statements（PDF/444KB)
• Value Chain Initiatives（PDF/716KB)
• Basic Knowledge of Pharmaceuticals（PDF/426KB)
• Corporate Profile / Shareholder Data（PDF/424KB)
• External Evaluations（PDF/518KB)